Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer

SMI-induced drug–drug interactions (DDIs) with frequently co-administered direct oral anticoagulants (DOACs), increase thromboembolic and bleeding risks. This study investigated and proactively managed the consequences of DOAC-SMI DDIs. This study enrolled patients with NSCLC concomitantly using a DOAC and SMI. Primary outcome was DOAC plasma trough and peak concentration. Data collection: descriptive characteristics, DOAC peak and trough concentrations, serious adverse events, bleeding and thromboembolic events.